Table 1 Landmark patient characteristics
Characteristic | Total | Arm A (nivo) | Arm B (cape) | Arm C (nivo + cape) |
|---|---|---|---|---|
N = 45 | N = 15 | N = 15 | N = 15 | |
Mean Age (SD) | 51.0 (11.5) | 46.3 (12.2) | 53.5 (8.8) | 53.1 (12.5) |
Race | ||||
  Black | 14 (31%) | 2 (13%) | 6 (40%) | 6 (40%) |
  White | 29 (65%) | 12 (80%) | 8 (53%) | 9 (60%) |
  Other | 2 (4%) | 1 (7%) | 1 (7%) | 0 |
Ethnicity | ||||
  Latino | 3 (7%) | 1 (7%) | 1 (7%) | 1 (7%) |
  Non-Latino | 42 (93%) | 14 (93%) | 14 (93%) | 14 (93%) |
NACT | ||||
  Taxane + anthracyclines | 42 (93%) | 14 (93%) | 15 (100%) | 13 (87%) |
  Taxanes only | 3 (7%) | 1 (7%) | 0 | 2 (13%) |
Neoadjuvant carboplatin | ||||
  Yes | 14 (31%) | 5 (33%) | 6 (40%) | 3 (20%) |
  No | 31 (69%) | 10 (67%) | 9 (60%) | 12 (80%) |
Prior radiotherapy | ||||
  Yes | 34 (76%) | 11 (73%) | 11 (73%) | 12 (80%) |
  No | 11 (24%) | 4 (27%) | 4 (27%) | 3 (20%) |
Known germline mutation | ||||
  BRCA1/2 | 3 (7%) | 2 (17%) | 1 (8%) | 0 |
  PALB2 | 2 (4%) | 0 | 2 (17%) | 0 |
Pathological staging (yp) | ||||
  I | 13 (29%) | 5 (33%) | 6 (40%) | 2 (13%) |
  II | 20 (44%) | 7 (47%) | 4 (27%) | 9 (60%) |
  III | 12 (27%) | 3 (20%) | 5 (33%) | 4 (27%) |
